Related Experiment Videos
Pentasa (Mesalamine)
Abstract:
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and unpredictable group of illnesses affecting the gastrointestinal tracts of over 2 million Americans. Pentasa causes few side effects and is generally well tolerated.
Insights
Pentasa, an oral 5-aminosalicylic acid capsule, is now available for treating ulcerative colitis. This new medication effectively induces remission and manages mild to moderate symptoms with a favorable side effect profile.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Ulcerative colitis is a chronic inflammatory bowel disease affecting over 2 million Americans.
- It is a debilitating gastrointestinal condition requiring effective management strategies.
Purpose of the Study:
- To introduce Pentasa (mesalamine) as a new oral treatment option.
- To highlight its efficacy in inducing remission and treating ulcerative colitis.
Main Methods:
- Oral administration of Pentasa (mesalamine) capsules.
- Clinical application for managing ulcerative colitis symptoms.
Main Results:
- Pentasa is indicated for the induction of remission in ulcerative colitis.
- It is effective for treating mildly to moderately active disease.
- The medication is generally well-tolerated with few side effects.
Conclusions:
- Pentasa offers a new therapeutic option for ulcerative colitis patients.
- Its tolerability and efficacy make it a valuable treatment choice.